Evidence map›Paper›PMID 36185208›Full record

ArticleFrontiers in oncology2022

Genomic landscape of advanced prostate cancer patients with

Umang Swami, Raquel Mae Zimmerman, Roberto H Nussenzveig, Edgar Javier Hernandez, Yeonjung Jo, Nicolas Sayegh, Sergiusz Wesolowski, Lesli A Kiedrowski, Pedro C Barata, Gordon Howard Lemmon and 11 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Umang SwamiDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Raquel Mae ZimmermanHuman Genetics, University of Utah, Salt Lake City, UT, United States.
Roberto H NussenzveigDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Edgar Javier HernandezHuman Genetics, University of Utah, Salt Lake City, UT, United States.
Yeonjung JoDivision of Oncology and Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Nicolas SayeghDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Sergiusz WesolowskiHuman Genetics, University of Utah, Salt Lake City, UT, United States.
Lesli A KiedrowskiDepartment of Medical Affairs, Guardant Health, Redwood City, CA, United States.
Pedro C BarataDeming Department of Medicine, Section of Hematology/Oncology, Tulane University Medical School, New Orleans, LA, United States.
Gordon Howard LemmonHuman Genetics, University of Utah, Salt Lake City, UT, United States.
Mehmet A BilenDepartment of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, United States.
Elisabeth I HeathDepartment of Oncology, Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, MI, United States.
Lakshminarayan NandagopalDepartment of Medical Oncology, University of Alabama Medical Center, Birmingham, AL, United States.
Hani M BabikerDepartment of Medical Oncology, Mayo Clinic Florida, Jacksonville, FL, United States.
Sumanta K PalGenitourinary Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA, United States.
Michael LillyDivision of Hematology and Oncology, Department of Medicine, Medical University of South Carolina, Charleston, SC, United States.
Benjamin L MaughanDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Benjamin HaalandDivision of Oncology and Department of Population Health Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
Mark YandellHuman Genetics, University of Utah, Salt Lake City, UT, United States.
Oliver SartorTulane Cancer Center, Tulane Medical School, New Orleans, LA, United States.
Neeraj AgarwalDivision of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, United States.
University of Utah · USHuntsman Cancer Institute · USCity of Hope · USEmory University · USGuardant (United States) · USMayo Clinic in Florida · USMedical University of South Carolina · USTulane Medical Center · USTulane University · USUniversity of Alabama · USWayne State University · US

Funding

TRAINING IN CARDIOVASCULAR RESEARCHT32HL007576 · NHLBI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Stavros George Drakos, Robin M Shaw · 1985 to 2026
$10.6M
NHLBI NIH HHS T32 HL007576
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

advanced prostate cancerBRCA1 vs. BRCA2 landscape by cfDNA BRCA1BRCA2ctDNAmachine learning

Identifiers

PMID36185208
PMCPMC9521349
OpenAlexW4295942692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.